Calypte und die Zeit nach AIDS2004 in Bangkok

na da denken aber nicht viele !

aber das mit dem "warte mal ab, was dann passieren wird" habe ich schon mal von dir gehört, als du weggeflogen bist...


was soll passieren? vielleicht kommen die testergebnisse, dann gibt es noch mal einen pop-up über die 0,20 bis in die bereiche 0,27 oder 0,28...

das wars dann aber auch. weiterhin keine umsätze und die grottigen Q-1 zahlen müssen ja auch noch kommen...

already replied but as a summary:

1. "New" investors have a lien on all assets of HIV. How do you common stock holders feel about that?

2. "New" investors get a 7% finders fee on stock and 4% finders fee on warrants. Wonder how hard Marr was to find?

New Financing $ 8,000,000
owed to Marr - 2,000,000 paid off the top
Balance 6,000,000
Advanced payment to TC - 375,000
Balance 5,625,000
Catch Magic up to date - 1,250,000
Balance 4,375,000
A/P and royalties due now -2,000,000
Balance 2,375,000 left with just the easy to find liabilities of HIV.

Well that should last until about June 1, if everyone is paid up to date at current cash burn rate of 1.1 million a month.

Maybe a simpler equation would be $ 8,000,000 owed at year end on current liabilities plus $ 2,000,000 loan from Marr = $ 10,000,000 current liabilities versus $ 8,000,000 cash. OOPS

Now you see why they say they would need 15 million to get through 2005.

5.5 million line of credit that can be withdrawn at any time is not real comforting.
By: roy_hinkley  
08 Apr 2005, 12:04 PM EDT

already replied but as a summary:


Looks like either Marr has HIV and retail investors hogtied, or HIV has Marr and retail investors hogtied.

Management can't lose as they get big salaries, have options only, own no stock to speak of, and don't serve on the Board of Directors.

and don't forget that all the "insiders" are making sure that all of their shares are registered for sale. None of that "lock up" stuff.

(Voluntary Disclosure: Position- No Position)

angepriesenen TRIB Trinity Biotech- der unschlagbaren Konkurrenz von Calypte ?! Sind auf einem neuen 52-Wochen-Tief ! Aber dazu hört man natürlich nichts von Dir ...

Übrigens danke für deinen Auszug aus RB. Du vergaßt die Quelle zu erwähnen (oder ists dir inzwischen selbst zu peinlich?!): ROY the toy Hinkley *loooool*

ist das joelu's grosser bruder? *g*

Wünsch euch eine gute Zeit - werde mich sicher mal von dort melden ...

Greetings to all LONGS and STRONGS !!!!

Kade_I

wer jetzt in trinity einsteigt, macht schnell mal 20%. der wert ist absolut unterbewertet!

TRINITY BIOTECH PLC ADR - Nasdaq SmallCap Market: TRIB

Share Related
Market Cap(Th.) 126,763.40
Common Shares Outst. 56,090
Average Daily Volume 227,700

kade, mk bei 126.763.400 $ bei GEWINN und einem umsatz von knapp 80 mio-$. mit dem vergleich schneidest du dir aber selber ins fleisch. KUV gerade mal 1,5!!!!!!!!!!!

stell dir vor, caly würde so bewertet!! muhahahahahahahahahahahahha

mk dann knapp 5 mio-$ bei 171 mio shares. fairer kurs dann bei 0,028$ muhahhahahahaa!!!!!!!!!

hier die aktuellen daten:

Support/Resistance
Type Value Conf.
resist. 0.42 2
resist. 0.40 2
resist. 0.38 2
resist. 0.36 3
resist. 0.34 2
resist. 0.33 12
resist. 0.31 4
resist. 0.30 12
resist. 0.28 4
resist. 0.26 10
resist. 0.25 2
resist. 0.24 4
resist. 0.23 2
supp 0.20 8

"...Fliege am Sonntag für 3 Wochen nach Kuala Lumpur / Malaysia ! Wart mal ab was in der Zeit passieren wird ;-) mein neues 6-Zimmer-Penthouse in München ist schon für mich reserviert -) "

was passieren wird? in dieser woche geht ihr unter 0,20$....muhahahhaahahaha... das wird passieren

ich habe es im urin, wie ihr immer so schön sagt...

die letzten trades, fette trades auch zu 0,22. das ist der anfang vom absacke auf 0,18$....später dann erstmal auf 0,12$...


Time & Sales  
Price Size Time
0.233 2500 15:09:39
0.23 2500 15:09:37
0.24 33300 15:09:24
0.24 600 15:07:09
0.23 1000 15:06:57
0.23 1000 15:06:53
0.23 9700 15:06:38
0.22 1000 15:03:46
0.23 600 14:38:02
0.23 5000 14:37:14
0.23 500 14:35:07
0.23 15000 14:31:44
0.23 2500 14:10:37
0.22 100 13:49:17
0.23 2000 13:46:42
0.23 2000 13:46:39
0.23 1000 13:46:20
0.22 75000 13:46:19
0.22 50000 13:44:47
0.22 50000 13:43:17
0.23 2400 13:40:29
0.23 600 13:40:25
0.22 50000 13:38:31
0.23 7800 13:35:29
0.23 5000 13:35:18
0.23 5000 13:35:18


wer es nicht glauben will, wird es bald spüren...

unwissende in den ruin getrieben werden und das schon seit jahren, jedoch konnte ich einige bisher davor bewahren ihre verluste auszubauen.

ihr wisst ja hoffentlich auch, dass euer amex-lisitng in gefahr ist!!!

vom kurs her erfüllt ihr sowieso nicht den mindestanspruch, habt ihn im grund auch nie erfüllt (mind. 3monate über 1$ zu notieren). das amex-listing wurde eh nur durch die hintertüre erhascht, nämlich über die mk von > 50 mio $. aber selbst dass schafft ihr nicht mehr, wie auch? ich sehe da ganz schwarz für euch...

Share Related
Market Cap(Th.) 39,891.464
Common Shares Outst. 171,208
Average Daily Volume 589,100

Income in Thousands of U.S. Dollars

                 12/2004 12/2003 12/2002 12/2001 12/2000

Operating Revenue 3,297     3,467  3,670    6,826    3,296
Adjustments to Revenue - - - - -
Cost of Revenue (6,790)      281   (4,166)  (5,131)  (4,996)
Gross Operating Profit (3,493) 3,748 (496)    1,695   (1,700)

Selling/General/Admin Expense (8,979) (15,517) (9,006) (6,740) (7,568)
Research & Development (2,140) (1,544) (929) (1,546) (2,254)
EBITDA (14,612) (13,313) (10,431) (6,591) (11,522)
Depreciation & Amortization (488) (6,402) (1,996) (1,855) (895)
EBIT (15,100) (19,715) (12,427) (8,446) (12,417)
Interest Income - - 3 9 289
Other Income, Net (38) 182 16 539 9
Total Income Avail For Interest Expense (15,138) (19,533) (12,408) (7,898) (12,119)
Interest Expense (2,126) (6,969) (2,206) (1,373) (123)
Pre-Tax Income (17,264) (26,502) (14,614) (9,271) (12,242)
Income Taxes (2) (2) (2) (2) (2)
Minority Interest - 90 - - -
Net Income from Continuing Operations (17,266) (26,414) (14,616) (9,273) (12,244)
Net Income from Discontinued Operations - - - - -
Net Income from Total Operations (17,266) (26,414) (14,616) (9,273) (12,244)

Normalized Income (17,266) (26,414) (14,616) (9,273) (12,244)
Extraordinary Income - - - - -
Special Income/Charges - - - - -
Income from Cum. Effect of Acct Change - - - - -
Income from Tax Loss Carryforward - - - - -
Other Gains - - 1,319 145 -
Total Net Income (17,266) (26,414) (13,297) (9,128) (12,244)

Das sind deine letzten Tage, deine Tage sind gezählt mein lieber Joelü..

Das du dich zum Affen machst , ist das eine ...

Man würde fast meinen, du würdest Provision dafür bekommen ...


Gruß

C.O

weil der kurs bald bei 0,50$ steht oder was? muahahahahahahahaaaaa

wenn hier vo jemandem die tage gezählt sind, dann sind es deine broker. auch ihr letzten hardliner (broker, lucky, kade, giants) seid bald mundtot...dann herrscht nur noch betretenes schweigen und peinvolles schwanzeinziehen...


die einsicht im stillen kämmerlein haben eingie von euch schon, ganz sicher. es verbietet sich nur, mal einen fehler zuzuzgeben, darum hört man noch eure hohlen durchhalteparolen. es gibt nichts fundiertes, was für euch spricht, nur:

1)pass auf was in den nächsten wochen kommt...
2)es werden umsätze in q-2 kommen
3)die testergebnisse kommen bald
4)die zulassungen sind bald da
5)es kommen großaufträge im 2 HJ...etc. bla bla bla-hup-und bläh

leute, nach dieser schlappe, bei der ihr mit dem brett-vorm-kopf darsteht, könnt ihr euch neue nicks suchen. man wird über eure sturheit lachen. aber egal - hauptsache offiziell die niederlage nicht eingestehen. man wird auf eure kommentare nichts mehr geben. alle um euch herum werden wissen, was mit caly los ist. nur ihr heuchelt noch den erfolg...ihr seid an seriösität nicht mehr zu überbieten!

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

hast du nicht?

zur erinnerung:

--------------------------------------------------

4295. was ich von dir will?                                  joelu   01.03.05 17:31  

beantworte meine frage!!!

"befürchtest du auch, dass jetzt im märz die ausgabe weiterer aktien angekündigt wird?"

--------------------------------------------------



 
   4296. Nein, befürchte ich genauso wenig wie   Kade_I   01.03.05 17:48  

ich es im November nicht befürchtet habe. Schon damals hast Du uns hier mit dem gleichen Mist genervt und lagst wieder Mal WIE SO OFT falsch. Seitdem wurden Deine angekündigten 80 Mio shares NICHT ausgegeben, obwohl es ja laut Deinen Aussagen hier bereits beschlossen war !!!

Wäre schön wenn Du mal einen Gang zurück schalten würdest- wäre angebracht, wenn man sich deine Historie und dein Versagen auf allen Linien betrachtet.
--------------------------------------------------

biz.yahoo.com/prnews/050516/clm088.html?.v=8

uh uh jetzt geht es ab!!

dieses woche ist unter anderem für caly gebucht *g*

*g*

Dr. J. Richard George, President and Chief Executive Officer said, "We are extremely satisfied with the outcome of the trials in Uganda and the subsequent recommendation by Dr. Biryahwaho, at the Uganda Virus Research Institute. This is the first regulatory approval that we have received for our rapid HIV testing platform and believe that it will be the first of many. We consider this to be the final hurdle to begin sales in Uganda and are currently in the process of finalizing an agreement with our distributor in this territory."

About Uganda:

Uganda, located in sub-Saharan Africa has a population of over 26 million according to the U.S. Central Intelligence Agency Fact book. According to the UNAIDS 2004 report on the global AIDS epidemic, as of the end of 2003, approximately 530,000 adults and children living with HIV/AIDS, down from an estimated 620,000 two years prior. The Company estimates that foreign and donor agency sources including USAID, the Global Fund and the World Bank, funded over $100 million in 2004 for AIDS testing and treatment in Uganda. It is estimated that over 1 millions HIV diagnostic tests were conducted in Uganda in 2004, most of these rapid tests.

About Calypte Biomedical:

Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB/A (No. 1) for the year ended December 31, 2004 and its subsequent filings with the SEC.


    Company Contact:              Investor Relations Contact:
    Richard George, CEO           Tim Clemensen,
    (925) 730-7200                Rubenstein Investor Relations
    email:rgeorge@calypte.com     Phone: (212) 843-9337
                                  email:tclemensen@rubensteinir.com

..und siehe im usmarkt bewegt sich was :)

yeah!!

Calypte Biomedical Announces Manufacturing Services and Management Agreement With Maxim Biomedical
PLEASANTON, Calif., May 16, 2005 /PRNewswire-FirstCall via COMTEX/ -- Calypte Biomedical Corporation (Amex: HIV) announced today that in conjunction with its previously announced restructuring plan, it has entered into a manufacturing services and management agreement with Maxim Biomedical, Inc. According to the terms of the agreement, going forward, Maxim will manufacture, ship and perform quality control procedures for Calypte's urine EIA, serum Western Blot and urine Western Blot HIV in vitro diagnostic tests. The manufacturing services agreement will continue for a limited time until a definitive asset purchase agreement can be consummated whereby Maxim would acquire Calypte's urine EIA, serum Western Blot and urine Western Blot HIV in vitro diagnostic test business. Subject to further due diligence on the part of Maxim, Maxim has indicated its desire to complete the asset purchase as soon as practicable.

Under the terms of the agreement and in conjunction with the restructuring plan, Calypte has terminated all of the manufacturing personnel at its Rockville facility; transferred its screening and supplemental test inventory to Maxim, and, subject to certain qualifications, will be reimbursed for all out of pocket costs associated with the business, including the real property and equipment lease payments related to Calypte's Rockville, Maryland facility.

Dr. J. Richard George, President and CEO said, "We are please to have concluded a contract manufacturing agreement for our lab-based products, and are delighted to have found a strong and able partner in Maxim Biomedical. This has been an important step in our restructuring plan and we look forward to completing a definitive agreement with Maxim in the current quarter."